WO1995009244A1 - Method of preparing arabinonucleotides - Google Patents
Method of preparing arabinonucleotides Download PDFInfo
- Publication number
- WO1995009244A1 WO1995009244A1 PCT/EP1994/002949 EP9402949W WO9509244A1 WO 1995009244 A1 WO1995009244 A1 WO 1995009244A1 EP 9402949 W EP9402949 W EP 9402949W WO 9509244 A1 WO9509244 A1 WO 9509244A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- general formula
- arabinonucleotides
- preparation
- fermentation
- iam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/32—Nucleotides having a condensed ring system containing a six-membered ring having two N-atoms in the same ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/824—Achromobacter
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/829—Alcaligenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/85—Flavobacterium
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/874—Pseudomonas
Definitions
- the invention relates to a method for producing arabinonucleotides of the general formula I.
- X represents a hydrogen atom or a fluorine atom, which is characterized in that
- wo ⁇ n Y is a hydrogen atom or a nitro group
- Z symbolizes two hydrogen atoms or two alkali metal atoms, fermented with a microorganism capable of phosphorylating nucleosides.
- these compounds are prepared by phosphorylation of the corresponding nucleosides (Bull, of th. Chem. Soc. Japan 42, 1969, 3505-3508), New Journal of Chem. 11, 1987, 779-785 and WO 9209604). In this process, heavily contaminated raw products are obtained, the purification of which is very complex and lossy.
- the method according to the invention enables these substances to be synthesized in a relatively simple manner in a substantially purer form than is possible using the previously known methods.
- Suitable phosphate donors include aryl phosphates, such as phenyl phosphate or p-nitrophenyl phosphate. Usually 2-5 mol of phosphate donor is used per mol of nucleoside to be converted.
- proteases found in bacteria are mostly alkaline proteases, which are zinc proteins and mostly require magnesium ions to develop their effectiveness, it is advisable to carry out the reaction in the presence of 0.2 to 4.0% of a water-soluble zinc salt, such as zinc sulfate dihydrate or optionally also in the presence of 0.01 to 0.3% of a water-soluble magnesium salt, such as magnesium sulfate heptahydrate.
- a water-soluble zinc salt such as zinc sulfate dihydrate
- magnesium salt such as magnesium sulfate heptahydrate
- the process according to the invention can be carried out under the same conditions which are usually used in the fermentation of substrates with bacterial cultures.
- the bacterial culture is grown in a suitable medium, the substrate and the auxiliary substances are added and the culture is fermented with stirring and aeration until a maximum substrate conversion is achieved.
- fermentation broths are generally obtained in which the process product is difficult to separate from the fermentation medium.
- the bacterial cultures are grown in a conventional medium, the bacteria are separated by centrifugation, washed, possibly freeze-dried - in order to make them storable - resuspended in an isotonic buffer solution, mixed with substrate and auxiliary substances and fermented at 20 to 40 ° C until maximum substrate conversion is achieved.
- the preparation of the batch is not difficult, the cell material is centrifuged off, the supernatant is concentrated and the precipitated process product, which can be contaminated by easily separable starting material, is filtered off.
- reaction mixtures shaken for 40 hours at 40 ° C at 60 revolutions per minute.
- the cells are centrifuged off at 8000 revolutions per minute, the supernatant is concentrated in the ratio evaporator at a maximum of 50 ° C to 1/20 of the original volume, the separated crude product is filtered off, washed with water and dried for 24 hours at 100 ° C and lOOOOPa.
- Example 1c Under the conditions of Example 1c, but with the addition of 16 g / l disodium p-nitrophenyl phosphate instead of 8 g / l, 2.0 g / l 2-fluoro-9 ( ⁇ -D-arabinofuranosyl) -9H-purine-6-amine 40 Shaken for hours at 40 ° C at 60 revolutions per minute. The reaction mixture is worked up as described in Example 1c and about 60% of 2-fluoro-9- (5-0-phosphono- ⁇ -D-arabinofuranosyl) -9H-purine-6-amine is obtained.
- Example 4 Under the conditions of Example 1c but with the addition of 40 g / l disodium p-nitrophenyl phosphate instead of 8 g / l, 2.0 g / l of 2-fluoro-9 ( ⁇ -D-arabinofuranosyl) -9H-purine-6-amine Shaken for 100 hours at 40 ° C at 60 revolutions per minute. The reaction mixture is worked up as described in Example 1c and about 85% of 2-fluoro-9- (5-0-phosphono- ⁇ -D-arabinofuranosyl) -9-H-purine-6-amine is obtained.
- Example 4 Example 4
- Example 1c Under the conditions of Example 1c but with the addition of 20 g / l disodium phenyl phosphate instead of 8 g / l disodium p-nitrophenyl phosphate, 2.0 g / l 2-fluoro-9 ( ⁇ -D-arabinofuranosyl) -9H-purine-6 - Shaken amine for 100 hours at 40 ° C at 60 revolutions per minute.
- the reaction mixture is worked up as described in Example 1c and about 50% of 2-fluoro-9- (5-0-phosphono- ⁇ -D-arabinofuranosyl) - 9H-purine-6-amine is obtained.
- Example 4 Under the conditions of Example 4 but with the addition of 30 g / l disodium phenyl phosphate instead of 20 g / l, 2.0 g / l 2-fluoro-9- ( ⁇ -D-arabinofuranosyl) -9H-purine-6-amine are reacted, prepared and 60% of 2-fluoro-9- (5-0-phosphono-ß-D-arabinofuranosal) -9-H-purine-6-amine is obtained.
- Example 4 Under the conditions of Example 4 but with the addition of 40 g / l disodium phenyl phosphate instead of 20 g l, 2.0 g / l of 2-fluoro-9- ( ⁇ -D-arabinofurynosyl) -9H-purine-6-amine are reacted and processed and 70% of 2-fluoro-9- (5-0-phosphono-ß-D-arabinofuranosyl) 9-H-purine-6-amine is obtained.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Verfahren zur Herstellung von ArabinonukleotidenProcess for the production of arabinonucleotides
Die Erfindung betrifft ein Verfahren zur Herstellung von Arabinonukleotiden der allgemeinen Formel IThe invention relates to a method for producing arabinonucleotides of the general formula I.
H OH woπnH OH woπn
X ein Wasserstoffatom oder ein Fluoratom darstellt, welches dadurch gekennzeichnet ist, daß manX represents a hydrogen atom or a fluorine atom, which is characterized in that
H OH worin X die oben genannte Bedeutung besitzt, in Gegenwart eines Arylphosphats der allgemeinen Formel IIIH OH where X has the meaning given above, in the presence of an aryl phosphate of the general formula III
woπn Y ein Wasserstoffatom oder eine Nitrogruppe undwoπn Y is a hydrogen atom or a nitro group and
Z zwei Wasserstoffatome oder zwei Alkalimetallatome symbolisiert, mit einem zur Phosphorylierung von Nucleosiden befähigten Mikroorganismus fermentiert. Die Arabinonucleotide der allgemeinen Formel I, das 9(5-0-Phosphono-ß-D- arabinofύranosyl)-9-H-purin-6-amin (=Vidarabinphosphat) und das 2-Fluor-9-(5-0- phosphono-ß-D-arabinofuranosyl)-9H-purin-6-amin (=Fludarabinphosphat) sind bekanntlich pharmakologisch wirksame Substanzen, die sich durch eine antivirale und cylostatische Wirksamkeit auszeichnen (EP-A 317,728 und WO 9209604).Z symbolizes two hydrogen atoms or two alkali metal atoms, fermented with a microorganism capable of phosphorylating nucleosides. The arabinonucleotides of the general formula I, the 9 (5-0-phosphono-ß-D-arabinofύranosyl) -9-H-purine-6-amine (= vidarabine phosphate) and the 2-fluoro-9- (5-0-phosphono -ß-D-arabinofuranosyl) -9H-purine-6-amine (= fludarabine phosphate) are known to be pharmacologically active substances which are distinguished by an antiviral and cylostatic activity (EP-A 317,728 and WO 9209604).
Nach den bekannten Verfahren werden diese Verbindungen durch Phosphorylierung der entsprechenden Nucleoside hergestellt (Bull, of th. Chem. Soc. Japan 42, 1969, 3505- 3508), New Journal of Chem. 11, 1987, 779-785 und WO 9209604). Bei diesem Verfahren erhält man stark verunreinigte Rohprodukte, deren Aufreinigung sehr aufwendig und verlustreich sind.According to the known methods, these compounds are prepared by phosphorylation of the corresponding nucleosides (Bull, of th. Chem. Soc. Japan 42, 1969, 3505-3508), New Journal of Chem. 11, 1987, 779-785 and WO 9209604). In this process, heavily contaminated raw products are obtained, the purification of which is very complex and lossy.
Das erfindungsgemäße Verfahren ermöglicht es, diese Substanzen in relativ einfacher Weise in wesentlich reinerer Form zu synthetisieren, als dies mittels der vorbekannten Verfahren möglich ist.The method according to the invention enables these substances to be synthesized in a relatively simple manner in a substantially purer form than is possible using the previously known methods.
Dies ist für den Fachmann überraschend. Aus den Untersuchungen von Koji Misugi et al. (Agr.Biol.Chem. 28, 1964, 586-600) ist zwar schon lange vorbekannt, daß man das Nucleosid Inosin mikrobiologisch phosphorylieren kann, man mußte aber erwarten, daß man bei der Phosphorylierung der Nucleoside der allgemeinen Formel II wesentlich ungünstigere Ergebnisse erzielen würde. Dies insbesondere aus zwei Gründen: Aus den Arbeiten v on Koji Mitsugi et al. ist bekannt, daß man bei der Phosphorylierung von Inosin oft Gemische isomerer Nucleotide erhält. Es war demzufolge zu erwarten, daß man bei der Phosphorylierung der Nucleoside der allgemeinen Formel II im gleichen - wenn nicht sogar im verstärkten Maße Isomerengemische erhalten würde.This is surprising for the person skilled in the art. From the studies by Koji Misugi et al. (Agr.Biol.Chem. 28, 1964, 586-600) has long been known that the nucleoside inosine can be microbiologically phosphorylated, but one had to expect that the phosphorylation of the nucleosides of the general formula II would achieve significantly less favorable results would. This is particularly for two reasons: From the work of Koji Mitsugi et al. it is known that mixtures of isomeric nucleotides are often obtained in the phosphorylation of inosine. It was therefore to be expected that the phosphorylation of the nucleosides of the general formula II would result in the same, if not increased, mixtures of isomers.
Es ist bekannt, daß Adenosin im Körperstoffwechsel unter Desamierung und Oxidation abgebaut wird (Römpps Chemie-Lexikon, 8te Auflage, Franckh'sche Verlagshandlung, Stuttgart (DE) 65) und es war demnach zu befürchten, daß bei der mikrobiologischen Umsetzung der Adenin-Derivate der allgemeinen Formel II zumindest partiell ebenfalls ein Abbau der Verbindungen eintreten würde.It is known that adenosine is broken down in the body metabolism with deamination and oxidation (Römpps Chemie-Lexikon, 8th edition, Franckh'sche Verlagshandlung, Stuttgart (DE) 65) and it was therefore to be feared that in the microbiological conversion of the adenine derivatives of the general formula II would also at least partially degrade the compounds.
Wie eigene Versuche, die mit dem auch von Koji Mitsugi et al. erwähnten Mikroorganismus Pseudomonas trifolii (IAM 1309 nach einer Untersuchung des DSM- Identifikationsdienstes ist seine ist er heute als Pantoeaagglomerans eingeordnet) treten die geschilderten befürchteten Nachteile bei der Phosphorylierung der Nucleoside der allgemeinen Formel II nicht auf, sondern die Reaktion scheint sogar noch günstiger zu verlaufen als diejenige des Inosins.Like my own experiments, which were also carried out by Koji Mitsugi et al. mentioned microorganism Pseudomonas trifolii (IAM 1309 after an investigation by the DSM identification service is his is today classified as a pantoea agglomerate), the described feared disadvantages occur in the phosphorylation of the nucleosides general formula II, but the reaction seems to be even more favorable than that of inosine.
Mit hoher Wahrscheinlichkeit kann das erfindungsgemäße Verfahren nicht ur mit dem getesteten Mikroorganismus Pseudomonas trifolii (IAM 1309), sondern auch mit anderen Mikroorganis-ien, die von Koji Mitsugi et al. als zur Phosphorylierung von Nucleosiden als geeignet beschrieben sind, durchgeführt werden. Es sind dies beispielsweise die Mikroorganismen:It is highly probable that the method according to the invention cannot be used only with the tested microorganism Pseudomonas trifolii (IAM 1309), but also with other microorganisms described by Koji Mitsugi et al. described as being suitable for phosphorylation of nucleosides. These are, for example, the microorganisms:
Pseudomonas trifolii IAM 1543 und IAM 1555Pseudomonas trifolii IAM 1543 and IAM 1555
Pseudomonas perlurdia IAM 1589, IAM 1600, IAM 1610 und IAM 1627,Pseudomonas perlurdia IAM 1589, IAM 1600, IAM 1610 and IAM 1627,
Pseudomonas melanogenum F-ll,Pseudomonas melanogenum F-ll,
Alcaligenes visco lactis ATCC 9039 und IFM AN-14,Alcaligenes visco lactis ATCC 9039 and IFM AN-14,
Achromobacter superficialis IAM 1433Achromobacter superficialis IAM 1433
Flavobacterium lactis IFM F101Flavobacterium lactis IFM F101
Flavobacterium fuscum IAM 1181Flavobacterium fuscum IAM 1181
Flavobacterium flavescens IFO 3085Flavobacterium flavescens IFO 3085
Flavobacterium breve IFM S-15Flavobacterium breve IFM S-15
Serracina marcesce s IAM 1022, IAM 1065, IAM 1067, LAM 1104, LAMSerracina marcesce s IAM 1022, IAM 1065, IAM 1067, LAM 1104, LAM
1135, IAM 1161, IAM 1205, IAM 1223, IAM 17031135, IAM 1161, IAM 1205, IAM 1223, IAM 1703
und weitere Mikroorganismen, die in dieser Publikation aufgeführt sind.and other microorganisms listed in this publication.
Das erfindungsgemäße Verfahren muß, um eine ausreichende Phosphorylierung der nur sehr aufwendig herstellbaren Arabinonucleoside der allgemeinen Formel II zu erzielen, in Gegenwart eines großen Überschusses an einem Phosphatdonator durchgeführt werden. Geeignete Phosphatdonatoren sind unter anderem Arylphosphate, wie das Phenylphosphat oder das p-Nitrophenylphosphat. Üblicherweise verwendet man pro mol umzusetzendem Nucleosid 2-5 mol Phosphatdonator. Da die in Bakterien vorkommenden Proteasen meist alkalische Proteasen sind, die Zinkproteine darstellen und meist Magnesiumionen zur Entfaltung ihrer Wirksamkeit benötigen, ist es zweckmäßig, die Umsetzung in Gegenwart von 0,2 bis 4,0 % eines wasserlöslichen Zinksalzes, wie zum Beispiel Zinksulfat-Dihydrat oder gegebenenfalls auch in Gegenwart von 0,01 bis 0,3 % eines wasserlöslichen Magnesiumsalzes, wie Magnesiumsulfat-Heptahydrat durchzuführen.The process according to the invention must be carried out in the presence of a large excess of a phosphate donor in order to achieve sufficient phosphorylation of the arabinonucleosides of the general formula II, which can be prepared only with great difficulty. Suitable phosphate donors include aryl phosphates, such as phenyl phosphate or p-nitrophenyl phosphate. Usually 2-5 mol of phosphate donor is used per mol of nucleoside to be converted. Since the proteases found in bacteria are mostly alkaline proteases, which are zinc proteins and mostly require magnesium ions to develop their effectiveness, it is advisable to carry out the reaction in the presence of 0.2 to 4.0% of a water-soluble zinc salt, such as zinc sulfate dihydrate or optionally also in the presence of 0.01 to 0.3% of a water-soluble magnesium salt, such as magnesium sulfate heptahydrate.
Abgesehen von den genannten Bedingungen kann das erfindungsgemäße Verfahren unter den gleichen Bedingungen durchgeführt werden, die man üblicherweise bei der Fermentation von Substraten mit Bakterienkulturen anwendet. Die Bakterienkultur wird in einem geeigneten Medium angezüchtet, das Substrat und die Hilfsstoffe -zugesetzt und die Kultur unter Rühren und Belüften fermentiert bis eine maximale Substratumwandlung erreicht wird.Apart from the conditions mentioned, the process according to the invention can be carried out under the same conditions which are usually used in the fermentation of substrates with bacterial cultures. The bacterial culture is grown in a suitable medium, the substrate and the auxiliary substances are added and the culture is fermented with stirring and aeration until a maximum substrate conversion is achieved.
Wendet man dieses Verfahen an, so erhält man in der Regel Fermentationsbrühen, bei denen das Verfahrensprodukt nur schwer vom Fermentationsmedium abtrennbar ist.If this method is used, fermentation broths are generally obtained in which the process product is difficult to separate from the fermentation medium.
Deshalb erscheint es in der Regel zweckmäßiger, die Reaktion unter den Bedingungen des resting-cell-Verfahrens durchzuführen. Zu diesem Zwecke werden die Bakterienkulturen in einem üblichen Medium angezüchtet, die Bakterien durch Zentrifugieren abgetrennt, gewaschen, eventuell gefriergetrocknet - um sie lagerfähig zu machen - in einer isotonischen Pufferlösung resuspendiert, mit Substrat und Hilfsstoffen versetzt und bei 20 bis 40°C fermentiert, bis eine maximale Substratumwandlung erreicht ist. Unter diesen Gegebenheiten bereitet die Aufbereitung des Ansatzes keine Schwierigkeiten, das Zellmaterial wird abzentrifugiert, der Überstand eingeengt und das ausgefallene Verfahrensprodukt, welches durch leicht abtrennbares Ausgangsmaterial verunreinigt sein kann, abfiltriert.For this reason, it generally seems more appropriate to carry out the reaction under the conditions of the resting cell method. For this purpose, the bacterial cultures are grown in a conventional medium, the bacteria are separated by centrifugation, washed, possibly freeze-dried - in order to make them storable - resuspended in an isotonic buffer solution, mixed with substrate and auxiliary substances and fermented at 20 to 40 ° C until maximum substrate conversion is achieved. Under these circumstances, the preparation of the batch is not difficult, the cell material is centrifuged off, the supernatant is concentrated and the precipitated process product, which can be contaminated by easily separable starting material, is filtered off.
Die nachfolgenden Ausführungsbeispiele dienen zur Erläuterung des erfindungsgemäßen Verfahrens: Beispiel 1The following exemplary embodiments serve to explain the method according to the invention: example 1
a) Eine Petrischale mit einem Medium enthaltenda) Containing a petri dish with a medium
1 % Pepton1% peptone
0,2 % Hefeextrakt0.2% yeast extract
0,1 % Magnesiumsulfat-Heptahydrat und0.1% magnesium sulfate heptahydrate and
1,5 % Agar1.5% agar
- eingestellt auf pH 7.0 -- adjusted to pH 7.0 -
wird mit einer Trockenkultur von Pseudomonas trifolii LAM 1309 beimpft und 16 Stunden bei 30° lang inkubiert.is inoculated with a dry culture of Pseudomonas trifolii LAM 1309 and incubated for 16 hours at 30 °.
b) Ein 2 1 Erlenmeyerkolben mit 1 1 Mediums enthaltendb) Containing a 2 1 Erlenmeyer flask with 1 1 medium
1 % Pepton1% peptone
0,2 % Hefeextrakt und0.2% yeast extract and
0,1 % Magnesiumsulfat-Heptahydrat0.1% magnesium sulfate heptahydrate
- eingestellt auf pH 7 -- adjusted to pH 7 -
wird mittels einer Öse mit der gemäß a) hergestellten Vorkultur beimpft und 16 Stun den lang bei 30°C mit 180 Umdrehungen pro Minute inkubiert. Dann werden die Zellen 15 Minuten lang mit 6000 Umdrehungen pro Minute bei 10°C abzentrifugiert, mit 200 ml einer 0,02%igen wässrigen Kaliumchloridlösung gewaschen, in 20 ml einer 0,02%igen wässrigen Kaliumchloridlösung suspendiert, bei -20°C eingefroren und 20 Stunden lang gefriergetrocknet. Zum Gebrauch werden die gefriergetrockneten Zellen bei Raumtemperatur gelagert.is inoculated by means of an eyelet with the preculture prepared according to a) and incubated for 16 hours at 30 ° C. at 180 revolutions per minute. The cells are then centrifuged at 6000 rpm for 15 minutes at 10 ° C., washed with 200 ml of a 0.02% aqueous potassium chloride solution, suspended in 20 ml of a 0.02% aqueous potassium chloride solution, frozen at -20 ° C. and freeze-dried for 20 hours. For use, the freeze-dried cells are stored at room temperature.
c) In Schraubflaschen werden in 0,5 M Natriumacetatpuffer von pH 4,5 pro 1c) In screw-top bottles are in 0.5 M sodium acetate buffer of pH 4.5 per 1
2,0 g 2-Fluor-9-(ß-DArabonofuranosyl)-9H-purin-6-amin,2.0 g of 2-fluoro-9- (ß-DArabonofuranosyl) -9H-purin-6-amine,
0,12 g Zinksulfat-Dihydrat, 1,0 g gemäß Beispiel lb hergestellte gefriergetrocknete Pseudomonat trifolii IAM 1309 Kultur und0.12 g zinc sulfate dihydrate, 1.0 g of freeze-dried Pseudomonat trifolii IAM 1309 culture and prepared according to Example 1b
8,0 g Dinatrium-p-nitrophenylphosphat8.0 g disodium p-nitrophenyl phosphate
eingetragen und die Reaktionsmischen 40 Stunden lang bei 40°C mit 60 Umdrehungen pro Minute geschüttelt.entered and the reaction mixtures shaken for 40 hours at 40 ° C at 60 revolutions per minute.
Dann zentrifugiert man die Zellen mit 8000 Umdrehungen pro Minute ab, engt den Überstand im Ratitionsverdampfer bei maximal 50°C auf 1/20 des ursprünglichen Volumens ein, filtriert das abgeschiedene Rohprodukt ab, wäscht es mit Wasser und trocknet es 24 Stunden lang bei 100°C und lOOOOPa.Then the cells are centrifuged off at 8000 revolutions per minute, the supernatant is concentrated in the ratio evaporator at a maximum of 50 ° C to 1/20 of the original volume, the separated crude product is filtered off, washed with water and dried for 24 hours at 100 ° C and lOOOOPa.
Laut HPLC Analyse des erhaltenen Rohprodukts sind bei diesem Versuch ca. 50% 2- Fluor-9-(5-0-phosphono-ß-D-arabinofuranosyl)-9Hpurin-6-amin gebildet worden.According to HPLC analysis of the crude product obtained, about 50% 2-fluoro-9- (5-0-phosphono-ß-D-arabinofuranosyl) -9Hpurin-6-amine was formed in this experiment.
Beispiel 2Example 2
Unter den Bedingungen des Beispiels lc, aber unter Zusatz von 16g/l Dinatrium-p- nitrophenylphosphat anstelle von 8g/l werden 2.0 g/1 2-Fluor-9(ß-D-arabinofuranosyl)-9H- purin-6-amin 40 Stunden lang bei 40°C mit 60 Umdrehungen pro Minute geschüttelt. Die Aufarbeitung der Reaktionsmischung erfolgt wie in Beispiel lc beschrieben und man erhält ca. 60% 2-Fluor-9-(5-0-phosphono-ß-D-arabinofuranosyl)-9H-purin-6-amin.Under the conditions of Example 1c, but with the addition of 16 g / l disodium p-nitrophenyl phosphate instead of 8 g / l, 2.0 g / l 2-fluoro-9 (β-D-arabinofuranosyl) -9H-purine-6-amine 40 Shaken for hours at 40 ° C at 60 revolutions per minute. The reaction mixture is worked up as described in Example 1c and about 60% of 2-fluoro-9- (5-0-phosphono-β-D-arabinofuranosyl) -9H-purine-6-amine is obtained.
Beispiel 3Example 3
Unter den Bedingungen des Beispiels lc aber unter Zusatz von 40g/l Dinatrium-p- nitrophenylphosphat anstelle von 8g/l werden 2,0 g/1 2-Fluor-9(ß-D-arabinofuranosyl)-9H- purin-6-amin 100 Stunden lang bei 40°C mit 60 Umdrehungen pro Minute geschüttelt. Die Aufarbeitung der Reaktionsmischung erfolgt wie in Beispiel lc beschrieben und man erhält ca. 85% 2-Fluor-9-(5-0-phosphono-ß-D-arabinofuranosyl)-9-H-purin-6-amin. Beispiel 4Under the conditions of Example 1c but with the addition of 40 g / l disodium p-nitrophenyl phosphate instead of 8 g / l, 2.0 g / l of 2-fluoro-9 (β-D-arabinofuranosyl) -9H-purine-6-amine Shaken for 100 hours at 40 ° C at 60 revolutions per minute. The reaction mixture is worked up as described in Example 1c and about 85% of 2-fluoro-9- (5-0-phosphono-β-D-arabinofuranosyl) -9-H-purine-6-amine is obtained. Example 4
Unter den Bedingungen des Beispiels lc aber unter Zusatz von 20g/l Dinatriumphenyl- phosphat anstelle von 8g/l Dinatrium-p-nitrophenylphosphat werden 2,0g/l 2-Fluor-9(ß-D- arabinofuranosyl)-9H-purin-6-amin 100 Stunden lang bei 40°C mit 60 Umdrehungen pro Minute geschüttelt. Die Aufarbeitung der Reaktionsmischung erfolgt wie in Beispiel lc beschrieben und man erhält ca. 50% 2-Fluor-9-(5-0-phosphono-ß-D-arabinofuranosyl)- 9H-purin-6-amin.Under the conditions of Example 1c but with the addition of 20 g / l disodium phenyl phosphate instead of 8 g / l disodium p-nitrophenyl phosphate, 2.0 g / l 2-fluoro-9 (β-D-arabinofuranosyl) -9H-purine-6 - Shaken amine for 100 hours at 40 ° C at 60 revolutions per minute. The reaction mixture is worked up as described in Example 1c and about 50% of 2-fluoro-9- (5-0-phosphono-β-D-arabinofuranosyl) - 9H-purine-6-amine is obtained.
Beispiel 5Example 5
Unter den Bedingungen des Beispiels 4 aber unter Zusatz von 30g/l Dinatrium- phenylphosphat anstelle von 20g/l werden 2,0g/l 2-Fluor-9-(ß-D-arabinofuranosyl)-9H- purin-6-amin umgesetzt, aufbereitet und man erhält 60% 2-Fluor-9-(5-0-phosphono-ß-D- arabinofuranosal)-9-H-purin-6-amin.Under the conditions of Example 4 but with the addition of 30 g / l disodium phenyl phosphate instead of 20 g / l, 2.0 g / l 2-fluoro-9- (β-D-arabinofuranosyl) -9H-purine-6-amine are reacted, prepared and 60% of 2-fluoro-9- (5-0-phosphono-ß-D-arabinofuranosal) -9-H-purine-6-amine is obtained.
Beispiel 6Example 6
Unter den Bedingungen des Beispiels 4 aber unter Zusatz von 40g/l Dinatrium- phenylphosphat anstelle von 20g l werden 2,0g/l 2-Fluor-9-(ß-D-arabinofurynosyl)-9H- purin-6-amin umgesetzt, aufbereitet und man erhält 70% 2-Fluor-9-(5-0-phosphono-ß-D- arabinofuranosyl)9-H-purin-6-amin. Under the conditions of Example 4 but with the addition of 40 g / l disodium phenyl phosphate instead of 20 g l, 2.0 g / l of 2-fluoro-9- (β-D-arabinofurynosyl) -9H-purine-6-amine are reacted and processed and 70% of 2-fluoro-9- (5-0-phosphono-ß-D-arabinofuranosyl) 9-H-purine-6-amine is obtained.
Claims
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE59409594T DE59409594D1 (en) | 1993-09-28 | 1994-09-06 | METHOD FOR PRODUCING ARABINONUCLEOTIDES |
| EP94927559A EP0721511B1 (en) | 1993-09-28 | 1994-09-06 | Method of preparing arabinonucleotides |
| AT94927559T ATE197720T1 (en) | 1993-09-28 | 1994-09-06 | METHOD FOR PRODUCING ARABINONUCLEOTIDES |
| DK94927559T DK0721511T3 (en) | 1993-09-28 | 1994-09-06 | Process for Preparation of Arabinonucleotides |
| JP51007995A JP4089978B2 (en) | 1993-09-28 | 1994-09-06 | Method for producing arabinonucleotide |
| US08/619,548 US5700666A (en) | 1993-09-28 | 1994-09-06 | Process for the production of arabinonucleotides |
| GR20010400276T GR3035445T3 (en) | 1993-09-28 | 2001-02-20 | Method of preparing arabinonucleotides |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4333727 | 1993-09-28 | ||
| DEP4333727.9 | 1993-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1995009244A1 true WO1995009244A1 (en) | 1995-04-06 |
Family
ID=6499328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1994/002949 Ceased WO1995009244A1 (en) | 1993-09-28 | 1994-09-06 | Method of preparing arabinonucleotides |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5700666A (en) |
| EP (1) | EP0721511B1 (en) |
| JP (1) | JP4089978B2 (en) |
| AT (1) | ATE197720T1 (en) |
| CA (1) | CA2172817A1 (en) |
| DE (1) | DE59409594D1 (en) |
| DK (1) | DK0721511T3 (en) |
| ES (1) | ES2153859T3 (en) |
| GR (1) | GR3035445T3 (en) |
| PT (1) | PT721511E (en) |
| WO (1) | WO1995009244A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1464708A1 (en) * | 2003-04-03 | 2004-10-06 | Pro. Bio. Sint. S.p.A. | A process for the preparation of fludarabine phosphate from 2-fluoroadenine |
| CN109072272A (en) * | 2016-01-20 | 2018-12-21 | 浙江海正药业股份有限公司 | A method for enzymatically preparing fludarabine phosphate |
| CN113584104A (en) * | 2021-08-04 | 2021-11-02 | 江苏海洋大学 | Method for synthesizing fludarabine phosphate through biocatalysis |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113173957B (en) * | 2021-04-28 | 2023-10-27 | 海南锦瑞制药有限公司 | Synthesis method and application of vidarabine monophosphate |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1517836A1 (en) * | 1965-12-10 | 1970-09-24 | Kyowa Hakko Kogyo Kk | Process for the preparation of 5'-purine nucleotides |
| WO1992009604A1 (en) * | 1990-11-29 | 1992-06-11 | Berlex Biosciences, Inc. | 6-azido-2-fluoropurine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602246A (en) * | 1992-11-25 | 1997-02-11 | Schering Aktiengesellschaft | Process for the preparation of fludarabine or fludarabine phosphate from guanosine |
-
1994
- 1994-09-06 DK DK94927559T patent/DK0721511T3/en active
- 1994-09-06 JP JP51007995A patent/JP4089978B2/en not_active Expired - Fee Related
- 1994-09-06 EP EP94927559A patent/EP0721511B1/en not_active Expired - Lifetime
- 1994-09-06 DE DE59409594T patent/DE59409594D1/en not_active Expired - Fee Related
- 1994-09-06 CA CA002172817A patent/CA2172817A1/en not_active Abandoned
- 1994-09-06 US US08/619,548 patent/US5700666A/en not_active Expired - Fee Related
- 1994-09-06 ES ES94927559T patent/ES2153859T3/en not_active Expired - Lifetime
- 1994-09-06 PT PT94927559T patent/PT721511E/en unknown
- 1994-09-06 AT AT94927559T patent/ATE197720T1/en not_active IP Right Cessation
- 1994-09-06 WO PCT/EP1994/002949 patent/WO1995009244A1/en not_active Ceased
-
2001
- 2001-02-20 GR GR20010400276T patent/GR3035445T3/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1517836A1 (en) * | 1965-12-10 | 1970-09-24 | Kyowa Hakko Kogyo Kk | Process for the preparation of 5'-purine nucleotides |
| WO1992009604A1 (en) * | 1990-11-29 | 1992-06-11 | Berlex Biosciences, Inc. | 6-azido-2-fluoropurine |
Non-Patent Citations (1)
| Title |
|---|
| PATENT ABSTRACTS OF JAPAN * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1464708A1 (en) * | 2003-04-03 | 2004-10-06 | Pro. Bio. Sint. S.p.A. | A process for the preparation of fludarabine phosphate from 2-fluoroadenine |
| WO2004087939A1 (en) * | 2003-04-03 | 2004-10-14 | Pro.Bio.Sint. S.P.A. | A process for the preparation of fludarabine phosphate from 2-fluoroadenine and fludarabine phosphate salts with amines or ammonia |
| CN109072272A (en) * | 2016-01-20 | 2018-12-21 | 浙江海正药业股份有限公司 | A method for enzymatically preparing fludarabine phosphate |
| CN113584104A (en) * | 2021-08-04 | 2021-11-02 | 江苏海洋大学 | Method for synthesizing fludarabine phosphate through biocatalysis |
| CN113584104B (en) * | 2021-08-04 | 2023-11-17 | 江苏海洋大学 | Method for synthesizing fludarabine phosphate by biocatalysis |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE197720T1 (en) | 2000-12-15 |
| EP0721511A1 (en) | 1996-07-17 |
| ES2153859T3 (en) | 2001-03-16 |
| DE59409594D1 (en) | 2000-12-28 |
| CA2172817A1 (en) | 1995-04-06 |
| EP0721511B1 (en) | 2000-11-22 |
| GR3035445T3 (en) | 2001-05-31 |
| US5700666A (en) | 1997-12-23 |
| JPH09502881A (en) | 1997-03-25 |
| DK0721511T3 (en) | 2001-03-05 |
| JP4089978B2 (en) | 2008-05-28 |
| PT721511E (en) | 2001-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE4004558C2 (en) | 6-mercaptopurine and 2-amino-6-mercaptopurine-9-ß-D-2 ', 3'-dideoxyribofuranoside, agents containing them, medicines and reagents and processes for the preparation of 2', 3'-dideoxypurine nucleosides | |
| DE68902670T2 (en) | KS-506 CONNECTIONS AND METHOD FOR THE PRODUCTION THEREOF. | |
| DE2743654B2 (en) | Anthracycline glycosides of group MA 144-, processes for their production and pharmaceutical preparations containing these glycosides | |
| EP0721511B1 (en) | Method of preparing arabinonucleotides | |
| DE69228438T2 (en) | Microbial process for the production of trans-4-hydroxy-L-proline | |
| DE69021716T2 (en) | METHOD FOR PRODUCING VANCOMYCIN. | |
| DE3027380A1 (en) | PRODUCTION OF A CEPHALOSPORINE BY FERMENTATION | |
| DE2722031A1 (en) | 9- (2-O-ACYL-BETA-D-ARABINOFURANOSYL) - ADENINE COMPOUNDS | |
| DE3785021T2 (en) | METHOD FOR PRODUCING NEURAMINIDASE. | |
| DE3611168C2 (en) | Hydroxybenzoesäurephenylester, their preparation and their use as physiologically active substances | |
| DE69106577T2 (en) | UCF1 compounds, their derivatives and processes for their preparation. | |
| DE2365894C2 (en) | Biotechnical process for the production of polynucleotides | |
| DE3003359C2 (en) | ||
| DE69222092T2 (en) | Microbial conversion of bile acids | |
| DE3031334C2 (en) | Microbiological process for the production of cholanic acid derivatives | |
| DE1695598B2 (en) | BIOTECHNICAL PROCESS FOR THE PRODUCTION OF 9- (BETA-D-ARABINOFURANOSYL) ADENINE | |
| DE2746209A1 (en) | NEW ANTIBIOTIC AND METHOD FOR MANUFACTURING IT | |
| DE1795481C (en) | Process for the preparation of 8 azapunnnucieosides excretion from 1470360 | |
| DE1130785B (en) | Process for the preparation of 5'-nucleotides, nucleosides and their mixtures by hydrolysis of ribonucleic acids, oligoribonucleotides or their mixtures | |
| DE2509337A1 (en) | PROCESS FOR THE PRODUCTION OF ANTIBIOTIC COMPOUNDS OF THE CEPHAMYCINTYPE | |
| DE1795480C3 (en) | Process for the preparation of purine nucleosides | |
| DE69225039T2 (en) | Microorganisms and process for the preparation of 3-alpha, 7-alpha-dihydroxy-12-keto-cholanic acid | |
| DE1470360C3 (en) | Process for the preparation of purine nucleosides | |
| DE1795721C2 (en) | Process for the fermentative production of orotidylic acid | |
| DE1517831C (en) | Use of fermentation liquids to obtain flavin adenine nucleotide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1994927559 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2172817 Country of ref document: CA |
|
| WWP | Wipo information: published in national office |
Ref document number: 1994927559 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 08619548 Country of ref document: US |
|
| WWG | Wipo information: grant in national office |
Ref document number: 1994927559 Country of ref document: EP |